Sustained release dosage forms

US9616036B2 · US · B2

Patent metadata
FieldValue
Publication numberUS-9616036-B2
Application numberUS-201314390046-A
CountryUS
Kind codeB2
Filing dateApr 8, 2013
Priority dateApr 11, 2012
Publication dateApr 11, 2017
Grant dateApr 11, 2017

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

A sustained release dosage form comprises an active ingredient blended with a polymeric matrix. At least a portion of the polymeric matrix is formed by a cellulose ether having an onset dissolution temperature of at least 40° C., having anhydroglucose units joined by 1-4 linkages and having methyl groups, hydroxyalkyl groups, and optionally alkyl groups being different from methyl as substituents such that the cellulose ether has an MS (hydroxyalkyl) of 0.05 to 1.00, and hydroxyl groups of anhydroglucose units are substituted with methyl groups such that [s23/s26−0.2*MS(hydroxyalkyl)] is 0.31 or less, wherein s23 is the molar fraction of anhydroglucose units wherein only the two hydroxyl groups in the 2- and 3-positions of the anhydroglucose unit are substituted with a methyl group and wherein s26 is the molar fraction of anhydroglucose units wherein only the two hydroxyl groups in the 2- and 6-positions of the anhydroglucose unit are substituted with a methyl group.

First claim

Opening claim text (preview).

What is claimed is: 1. A sustained release dosage form comprising at least one active ingredient blended with a polymeric matrix, wherein at least a portion of the polymeric matrix is formed by at least one cellulose ether having an onset dissolution temperature of at least 40° C., having anhydroglucose units joined by 1-4 linkages and having methyl groups, hydroxyalkyl groups, and optionally alkyl groups being different from methyl as substituents such that said at least one cellulose ether has an MS (hydroxyalkyl) of 0.05 to 1.00, and hydroxyl groups of anhydroglucose units are substituted with methyl groups such that s23/s26−0.2*MS(hydroxyalkyl) is 0.31 or less, wherein s23 is the molar fraction of anhydroglucose units wherein only the two hydroxyl groups in the 2- and 3-positions of the anhydroglucose unit are substituted with a methyl group and wherein s26 is the molar fraction of anhydroglucose units wherein only the two hydroxyl groups in the 2- and 6-positions of the anhydroglucose unit are substituted with a methyl group, and wherein said at least one cellulose ether has an onset dissolution temperature of at least 40° C., measured at a concentration of 2 weight percent in water and wherein the amount of said at least one cellulose ether is at least 10 percent, based on the total weight of the dosage form. 2. The sustained release dosage form of claim 1 wherein said at least one cellulose ether has an onset dissolution temperature of at least 45° C. 3. The sustained release dosage form of claim 1 wherein said at least one cellulose ether is a hydroxyalkyl methyl cellulose. 4. The sustained release dosage form of claim 3 wherein said at least one cellulose ether is a hydroxypropyl methyl cellulose. 5. The sustained release dosage form of claim 1 wherein said at least one cellulose ether has a DS(methyl) of 1.2 to 2.2. 6. The sustained release dosage form of claim 5 wherein said at least one cellulose ether has a DS(methyl) of 1.60 to 2.05. 7. The sustained release dosage form of claim 1 wherein said at least one cellulose ether has an MS (hydroxyalkyl) of 0.20 to 0.40. 8. The sustained release dosage form of claim 1 wherein said at least one cellulose ether has a viscosity of at least 50 mPa·s, determined as a 1.5% by weight solution in water in a Haake rheometer at 20° C. and at a shear rate of 2.55 s −1 . 9. A process for preparing a sustained release dosage form comprising the steps of I.) blending one or more cellulose ethers, one or more active ingredients, and one or more optional adjuvants, and II.) compressing the blend to a dosage form, wherein at least one cellulose ether has anhydroglucose units joined by 1-4 linkages wherein the ether substituents are methyl groups, hydroxyalkyl groups, and optionally alkyl groups being different from methyl, the cellulose ether has an MS (hydroxyalkyl) of 0.05 to 1.00, and hydroxyl groups of anhydroglucose units are substituted with methyl groups such that s23/s26−0.2*MS(hydroxyalkyl) is 0.31 or less, wherein s23 is the molar fraction of anhydroglucose units wherein only the two hydroxyl groups in the 2- and 3-positions of the anhydroglucose unit are substituted with a methyl group and wherein s26 is the molar fraction of anhydroglucose units wherein only the two hydroxyl groups in the 2- and 6-positions of the anhydroglucose unit are substituted with a methyl group, and wherein said at least one cellulose ether has an onset dissolution temperature of at least 40° C., measured at a concentration of 2 weight percent in water and wherein the amount of said at least one cellulose ether is at least 10 percent, based on the total weight of the dosage form. 10. The process of claim 9 wherein said at least one cellulose ether has an onset dissolution temperature of at least 45° C. 11. The process of claim 9 wherein said at least one cellulose ether is a hydroxyalkyl methyl cellulose. 12. The process of claim 9 wherein said at least one cellulose ether is a hydroxypropyl methyl cellulose. 13. The process of claim 9 wherein said at least one cellulose ether has a DS(methyl) of 1.60 to 2.05. 14. The process of claim 9 wherein said at least one cellulose ether has an MS (hydroxyalkyl) of 0.20 to 0.40. 15. The process of claim 9 wherein said at least one cellulose ether has a viscosity of at least 50 mPa·s, determined as a 1.5% by weight solution in water in a Haake rheometer at 20° C. and at a shear rate of 2.55 s −1 .

Assignees

Inventors

Classifications

  • with hydroxylated hydrocarbon radicals; Esters, ethers, or acetals thereof · CPC title

  • A61K31/167Primary

    having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol · CPC title

  • Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose · CPC title

  • Mixed ethers, i.e. ethers with two or more different etherifying groups · CPC title

  • with hydroxylated hydrocarbon radicals · CPC title

Patent family

Related publications grouped by family.

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US9616036B2 cover?
A sustained release dosage form comprises an active ingredient blended with a polymeric matrix. At least a portion of the polymeric matrix is formed by a cellulose ether having an onset dissolution temperature of at least 40° C., having anhydroglucose units joined by 1-4 linkages and having methyl groups, hydroxyalkyl groups, and optionally alkyl groups being different from methyl as substituen…
Who is the assignee on this patent?
Dow Global Technologies Llc
What technology area does this patent fall under?
Primary CPC classification A61K31/167. Mapped technology areas include Human Necessities.
When was this patent published?
Publication date Tue Apr 11 2017 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).